Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related PAY
Jim Cramer Shares His Thoughts On VeriFone Systems And BlackBerry
CNBC's Stock Pops & Drops From December 17
Google's Digital Wallet Initiative A Boon For The Mobile Payments Theme, Not Necessarily For Google (Seeking Alpha)
Related PWR
DA Davidson Tweaks Estimates For 6 Stocks
Benzinga's Top #PreMarket Losers
Why The 20%+ Drop In Quanta Services Is A Buying Opportunity (Seeking Alpha)

Pre-open movers US stock futures are lower this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average tumbled 31 points to 13,858.00 and S&P 500 index futures fell 3 points to 1,504.10. Nasdaq 100 futures dropped 11 points to 2,726.50.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 1.20%, London's FTSE 100 Index dipped 1.56%, French CAC 40 Index fell 1.72% and German DAX 30 index declined 1.73%.

Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.39%, China's Shanghai Composite falling 2.97% and Australia's S&P/ASX 200 dropping 2.26%. Hong Kong's Hang Seng Index tumbled 1.72% and India's Sensex fell 1.62%.

Broker Recommendation Analysts at Piper Jaffray downgraded VeriFone Systems (NYSE: PAY) from “overweight” to “neutral.” The target price for VeriFone has been lowered from $42 to $24.

VeriFone shares tumbled 35.25% to $20.65 in pre-market trading.

Breaking news

  • Quanta Services (NYSE: PWR) reported a 49% rise in its fourth-quarter earnings. To read the full news, click here.
  • Sirona Dental Systems (NASDAQ: SIRO) announced that Jeffrey T. Slovin has become its Chief Executive Officer in accordance with the succession plan previously announced on November 16, 2012. To read the full news, click here.
  • Host Hotels & Resorts (NYSE: HST) reported a 12% drop in its fourth-quarter profit. To read the full news, click here.
  • Repros Therapeutics (NASDAQ: RPRX) today provided a clinical update of its Androxal^® Phase 3 program following receipt of written guidance from the FDA. To read the full news, click here.

Posted-In: Piper Jaffray US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (HST + PAY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→